pSivida Corp.
(NASDAQ : PSDV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading PSDV News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.04%68.550.9%$505.54m
AMGNAmgen Inc.
0.37%163.321.1%$461.64m
BIIBBiogen Inc.
-1.94%271.211.2%$423.43m
CELGCelgene Corporation
0.07%124.051.2%$383.45m
REGNRegeneron Pharmaceuticals, Inc.
5.97%388.492.7%$332.95m
ALXNAlexion Pharmaceuticals, Inc.
0.69%127.781.9%$250.96m
INCYIncyte Corporation
0.09%124.282.6%$247.36m
VRTXVertex Pharmaceuticals Incorporated
0.75%118.301.9%$235.75m
ILMNIllumina, Inc.
0.61%184.863.5%$200.54m
TSROTESARO, Inc.
0.67%147.5914.7%$130.72m
NBIXNeurocrine Biosciences, Inc.
-0.36%53.405.3%$114.24m
BMRNBioMarin Pharmaceutical Inc.
-0.40%95.884.5%$113.09m
KITEKite Pharma, Inc.
-0.68%82.0816.6%$94.29m
AAgilent Technologies, Inc.
-0.70%55.041.5%$93.33m
SRPTSarepta Therapeutics, Inc.
4.44%36.2619.8%$82.73m

Company Profile

pSivida Corp. develops tiny, sustained-release products, which are designed to deliver drugs and biologics at a controlled and steady rate for weeks, months or years. The company through its technology platforms Duraser and Tethadur is focused on treatment of chronic diseases of the back of the eye and are also exploring applications outside ophthalmology. It is also developing a bioerodible, injectable micro-insert delivering latanoprost to treat glaucoma and ocular hypertension. pSivida was founded by Roger Aston in March 2008 and is headquartered in Waterson, MA.